You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
PET Probes for Senescence Detection in Brain
SBC: Senotrac Biotechnology LLC Topic: NIAPROJECT SUMMARYAround 50 million people worldwide are suffering from Alzheimer’s disease (AD) and related dementias, and AD is observed primarily in aged people. Current diagnosis of AD relies primarily on observations of declines in mental and cognitive functions, when irreversible brain damage occurs. Positron emission tomography (PET) tracers for early diagnosis of AD have been developed via ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Advancing mGlu1 positive allosteric modulators as therapeutics to facilitate abstinence in cocaine use disorder
SBC: ELEUTHERIA PHARMACEUTICALS LLC Topic: NIDAProject Summary A major challenge in treating cocaine use disorder is that vulnerability to cue-induced craving and relapse persist even after long periods of abstinence. There is presently no FDA-approved medication to lessen cocaine craving. The goal of Eleutheria Pharmaceuticals LLC is to develop metabotropic glutamate receptor 1 (mGlu1) positive allosteric modulators (PAMs) as therapeutic agen ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A Normal Paradigm to Monitor Perinatal Asphyxia Using A Combined Ultrasound-Neuromodulation and Photoacoustic-Imaging Device
SBC: BRIMROSE TECHNOLOGY CORP Topic: NIBIBPROJECT SUMMARYThe Brimrose Technology Corporation and partner, The Johns Hopkins University, propose using non-invasive ultrasound neuromodulation to identify hypoxic-ischemic encephalopathy (HIE) in newborns to reduce death and lifelong brain injury. HIE is the leading cause of neonatal death and impacts 2-6 of every 1,000 live births in the developed world. Our goal is to investigate and demons ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Provenance attestation of human cells using physical unclonable functions
SBC: SyntaxisBio Inc. Topic: NHGRIProject Summary The use of clustered regularly interspaced short palindromic repeats (CRISPR) technologies has spurred myriads of applications critically relevant to human health and, pertinent to the topic of this project, an ecosystem of companies, universities, and governmental laboratories that either offer or are in need of custom CRISPR- based cell line engineering has started to emerge. For ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Repurposing CRH antagonists for the treatment of endometriosis
SBC: SUR180 THERAPEUTICS, INC. Topic: NICHDPROJECT SUMMARY Endometriosis is a chronic condition that affects 10% of reproductive-aged women worldwide. Unfortunately, up to 59% of women with endometriosis do not respond to the available treatments and continue to suffer from endometriosis-associated pain or recurrent pain after treatment cessation. Therefore, treatment alternatives that deviate from the current therapeutic focus are urgentl ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development and Pre-Clinical Testing of Antimicrobial PEKK/Silicon Nitride Trauma Plates with Carbon Fiber Reinforcement
SBC: SINTX TECHNOLOGIES, INC. Topic: NIAMSPROJECT SUMMARY—More than 2 million Americans are hospitalized each year with bone fractures, and many more undergo outpatient procedures for fracture reduction and fixation. Some injuries can be treated with closed reduction and splinting or casting to immobilize the bone during healing. However, at some sites, more than half of fractures require open reduction and internal fixation. Despite ad ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Smartphone App to Increase and Maintain Physical Activity in African American Men (FitBrothers)
SBC: KLEIN BUENDEL, INC. Topic: 102Physical activity (PA) is a modifiable risk factor for a number of preventable chronic diseases, including cardiovascular disease, strokes, obesity, and diabetes. These conditions constitute health disparities for African American men. Behavioral interventions have proven to be effective in promoting increases in physical activity. While behavior change programs have been shown to assist participa ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Protection of donor kidneys with synchronization modulation electric field (SMEF)
SBC: WR Biotech, LLC Topic: 400The goals of this Phase II application: 1) determine the translational significance of the i-SMEF (improved Synchronization Modulation Electric Field) in a preclinical animal model using adult Yorkshire pigs with kidney autotransplantation; and 2) determine the optimal parameters of the i-SMEF in protection against ischemic injury of the donor kidneys during cold storage and improvement of the tra ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
STING Activators as Therapy for Cancer
SBC: STINGINN, LLC Topic: 102PROJECT SUMMARY The Immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body’s own immune system to fight cancer. The generation of anti-cancer T cells is predominantly triggered by phagocytosed cancer cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC’s). This signaling process is largely governed by STING (stimulator o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma
SBC: Up Therapeutics LLC Topic: NCIAbstract. Glioblastoma (GBM) is an aggressive and deadly brain cancer with a one year median survival due to the lack of effective targeted treatments. Our goal is to develop a small molecule inhibitor targeting RPN13 protein in the 19S proteasome complex as a new drug for GBM. RPN13 is a proteasome ubiquitin receptor that recognizes ubiquitin-conjugated proteins that are thus tagged for degradati ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health